Navigation Links
Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule
Date:3/22/2011

MADISON, Wis., March 22, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI) announced today that their two-year collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) to substantiate CDI's iCell® Cardiomyocytes as a predictive tool for assessing the potential cardiotoxic effects of developing drug candidates was completed early and is now transitioning into a standard supply agreement.  Moving forward, iCell Cardiomyocytes, induced pluripotent stem cell (iPSC)-derived human heart cells, will be incorporated into Roche's drug development decision-making process.

CDI and Roche initiated their collaboration in March 2009 to interrogate CDI's iCell Cardiomyocytes against a well-categorized compound reference set intended to test the ability of the cardiomyocytes to predict drug-induced, potentially life-threatening, cardiac arrhythmias. These studies included longitudinal genetic and molecular characterizations of the cardiomyocytes and assessment of their performance across a variety of established and novel testing platforms designed to detect possible cardiotoxic effects of developing compounds early in their development cycle.  Multiple publications based on this research are in preparation for submission to peer-reviewed journals.

"This transition to a standard supply agreement is an important milestone for CDI," said Chris Parker, Chief Commercial Officer of CDI.  "CDI and Roche have developed and demonstrated, respectively, a more efficient tool to reveal potential cardiotoxicity in their drug development candidates.  iCell Cardiomyocytes have proven to provide value to pharmaceutical drug discovery and development."

Robert Palay, CEO and Chairman of the Board of CDI, added, "We have developed iCell Cardiomyocytes as a cardiac cell model that truly reflects human biology. In addition, we have developed a manufacturing process that enables us to reliably deliver the cells in the quantity, quality and purity that our customers require to successfully accomplish their drug discovery and toxicity testing research.  We look forward to continuing our relationship with Roche and enabling them to discover future drug candidates that could improve human health."

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications.  CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools.  In addition, it is the leader in iPS cell technology, the production of pluripotent stem cell lines from adult tissue.  CDI was founded in 2004 by Dr. James Thomson, a pioneer in human embryonic stem cell research at the University of Wisconsin-Madison.  CDI's facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.


'/>"/>
SOURCE Cellular Dynamics International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
2. SecuraTrac Reveals Revolutionary Safety Solution Based on GPS & Cellular Technology at CES 2011
3. Transposagen and Cellular Dynamics International Cross-License Technologies for Induced Pluripotent Stem Cells
4. Largest Acellular Dermal Allografts for Abdominal Wall Repair Now Available From MTF
5. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
6. Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
7. Cellular Dynamics Partners with iPS Academia Japan, Inc. to In-License Seminal iPS Cell Patent Portfolio
8. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
9. Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening
10. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
11. Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Research and Markets has announced the addition of ... offering. ... report forecasts the global optical transceiver market to grow at a ... report covers the present scenario and the growth prospects of the ... the report considers the revenue generated from the shipment of optical ...
(Date:12/9/2016)...  Harmar Mobility, LLC announced today that Steven E. Dawson has been ... of Directors. Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... Harmar ... Mr. Dawson,s executive career includes leadership roles managing ... of industries. He brings to the company deep operational and leadership expertise, ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a ... to address severe, rare diseases, today announced that senior management will ... Success Healthcare Conference at the InterContinental Barclay Hotel in ... 4:20 p.m. ET. About aTyr Pharma ... aTyr Pharma is engaged ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... The ... Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits and ... the District of Columbia as an education tool in the war against teen drug ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest ... readers to sign up as an organ donor for the 123,000 people in the ... organ donor can save up to 8 saves through organ donation and enhance many ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... "I had ... an inventor from Winchester, Va. "I thought that if the nebulizer had a more ... rather than fearing them." , He developed the patent-pending NEBY to avoid the need ...
(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... ... 2016 , ... ZyDoc , a New York-based medical ... Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” has ... usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ natural ...
Breaking Medicine News(10 mins):